About
Prucalopride is a highly selective, high-affinity serotonin 5-HT4 receptor agonist specifically indicated for the symptomatic treatment of chronic idiopathic constipation in adults. It is prescribed for patients for whom conventional laxatives have failed to provide adequate relief. The mechanism of action involves stimulating the 5-HT4 receptors located in the gastrointestinal tract, which in turn enhances colonic motility and promotes coordinated bowel movements. This prokinetic action helps to normalize bowel function, reduce the effort and straining associated with defecation, and improve stool consistency, thereby significantly alleviating the discomfort and debilitating symptoms of chronic constipation. Prucalopride acts as a motility agent, helping to restore the natural rhythm and function of the gut rather than merely softening stools or increasing bulk.
Uses
- Treatment of chronic idiopathic constipation.
- When laxatives are ineffective.
- Improvement of bowel function.
- Relief of constipation symptoms in adults.
Directions For Use
Take orally once daily, with or without food. Swallow the tablet whole with water.
Benefits
- Effectively relieves chronic constipation.
- Improves bowel movement frequency.
- Reduces straining during defecation.
- Enhances stool consistency.
- Acts as a prokinetic agent.
- Improves quality of life for patients.
Side Effects
- Headache
- Nausea
- Abdominal pain
- Diarrhea
- Fatigue
- Dizziness
- Flatulence
- Vomiting
- Dyspepsia
- Anorexia
- Palpitations (rare)
- Tremor (rare)
Safety Measures
- Alcohol - No specific interaction with alcohol is known, but moderate consumption is generally advised.
- Pregnancy - Not recommended during pregnancy due to insufficient data; use only if clearly necessary and potential benefits outweigh risks.
- Breastfeeding - Excreted in human milk; not recommended during breastfeeding as potential effects on the infant are unknown.
- Liver - No dose adjustment is typically required for mild to moderate hepatic impairment; caution is advised in severe impairment.
- Kidney - Dose adjustment is required for severe renal impairment (eGFR <30 mL/min/1.73m²); not recommended for end-stage renal disease.
- Lung - No specific contraindications or dose adjustments related to lung conditions are typically required.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!